Genetic testing for persistent high-risk HPV after treatment
Part of Cancer, Digestive system, Women’s health & pregnancy clinical trials.
This study uses a detailed DNA test to look for high-risk HPV in people with long-lasting (chronic) infection after treatment or with return of abnormal cells. It may help improve how clinicians monitor high-risk HPV and decide next steps.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a long-lasting high-risk HPV infection (not just low-risk HPV).
- This may be present as early as 6 months after treatment of a cervix/vaginal injury, or it may be a return (recurrence) of abnormal cells or cancer.
- You have had a previous cervical or vaginal treatment for injury, high-grade cells, or cancer (so there is something to monitor again).
- You agree to join and sign the consent form.
- You are covered by a social security health scheme.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with severe or hard-to-treat HPV-related conditions (and some closely related partners/household contacts) to learn how the virus causes illness and how the immune system responds. It may help doctors better predict who will develop severe disease and guide future treatments.
This study looks at how to sort people into higher- or lower-risk groups after abnormal HPV testing treatment (LEEP), using repeat HPV and Pap (cytology) tests. It may help improve follow-up plans by identifying who needs closer monitoring after LEEP.
This trial collects blood samples from women with HPV-related cervical cancer to see if a test can detect tiny bits of cancer DNA (molecular residual disease) and predict if the cancer might come back. Finding this DNA early could help guide future treatment decisions.
This early (Phase 1) study tests a new treatment for people with long-lasting mild abnormal Pap test results (ASC-US or LSIL) who also have HPV16 found on testing. It aims to find out whether the treatment can be given safely and may affect the HPV and abnormal cell changes.
This study looks at follow-up care for anal (rear passage) HPV risk in adults who previously had high-risk HPV–related gynecologic changes. It aims to better track disease that may be related to HPV and possibly help guide future monitoring.
This study checks whether a blood test for HPV16 DNA can predict when HPV-related throat cancer comes back after treatment. It may help improve follow-up care by catching recurrence earlier.
Hear when a new Human Papillomavirus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.